Personalized Omega-3 Treatment in Depression

Prof. Kuan-Pin Su

 

Professor & Chairman

Professor and Vice Dean, College of Medicine, China Medical University, Taichung, Taiwan

Director, Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan

 

Depression is one of the leading causes of morbidity and mortality in medicine. Current available treatments clearly do not meet clinical needs, while clinicians and researchers are facing the huge challenge of developing effective depression treatments despite of the advance of neurosciences. As detailed in our Consensus Statements in the Lancet Psychiatry and World Psychiatry, nutritional medicine is a promising strategy for the crisis of under-effectiveness in depression treatment (1,2). Omega-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have a range of neurobiological activities in modulation of neurotransmitters, anti-inflammation, anti-oxidation and neuroplasticity, by which could contribute to the antidepressant effects (3-5). Evidence from epidemiological, pre-clinical, and clinical studies have revealed that omega-3 PUFAs play an important role in the treatment and prevention of certain subgroups of clinical depression (6-9). According to biological specificity and safety consideration, omega-3 PUFAs is a potential antidepressant treatment for pregnant women, children, adolescents, and inflammation-related depression. Omega-3 PUFAs are well tolerated and accepted by general populations for health promoting (10). Thus, more research on stratifying depression is needed to justify the clinical application of omega-3 PUFAs as one of the first-line antidepressant treatments in specific populations with depression.

 

Reference

  • Sarris J, et al. World Psychiatry 2015; 15: 370-1.
  • Sarris J, et al. Lancet Psychiatry 2015; 2(3): 271-4.
  • Lu DY, et al. Neuropsychopharmacology 2010; 35(11): 2238–2248.
  • Lin PY, et al. Biological Psychiatry 2010; 68(2):140-147.
  • Su KP*, et al. Progress in Neuro-Psychopharmacology & Biological Psychiatry (Accepted)
  • Lin PY, et al. Molecular Psychiatry 2012; 17(12): 1161-3.
  • Chang JPC, et al. Brain, Behavior, and Immunity 2015; 44: 28-31.
  • Su KP, et al. Biological Psychiatry 2014 Oct 1; 76(7): 559-66.
  • Song C, et al. Progress in Lipid Research 2016; 62: 41-54.
  • Su KP*. Journal of Clinical Psychiatry 2015; 76 (11): e1476-7.